Takeda Pharmaceutical’s long-serving research and development chief Andy Plump is set to retire, marking the end of a significant era for the Japanese drugmaker.
Plump has been a central figure in shaping Takeda’s research strategy over his tenure, overseeing a pipeline that spans multiple therapeutic areas including oncology, rare diseases, and neuroscience.
His departure signals a major leadership transition at one of Asia’s largest pharmaceutical companies at a time when the industry faces mounting pressure to deliver on costly drug development programmes.
Takeda has invested heavily in its R&D operations in recent years, and Plump’s exit will prompt close attention from investors and analysts watching the company’s next strategic moves.
In separate industry news, Daiichi Sankyo successfully defended itself against a substantial legal challenge, beating back a $1.3 billion damage claim brought against the company in a lawsuit.
The outcome represents a significant legal victory for Daiichi Sankyo, which has been one of the most closely watched pharmaceutical firms globally following its high-profile antibody-drug conjugate partnerships.
The case had drawn considerable attention given the scale of the damages sought, and the ruling removes what would have been a major financial liability from the company’s books.
Meanwhile, Samsung Biologics has secured a new manufacturing contract worth $262 million with an unnamed client, further cementing its position as one of the world’s leading contract development and manufacturing organisations.
The deal reflects continued strong demand for biologics manufacturing capacity as pharmaceutical and biotech companies seek reliable partners to produce complex therapies at scale.
Samsung Biologics has aggressively expanded its manufacturing footprint in recent years, and contracts of this size demonstrate that global clients continue to place significant confidence in its capabilities and infrastructure.
Taken together, these developments illustrate the pace at which strategic, legal, and commercial activity continues to reshape the global pharmaceutical landscape heading further into 2026.